Human VHL antibody

Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition todevelop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas andhemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in theVHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-typeallele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet (beta-domain) anda smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL proteinis also involved in the degradation of hypoxia-inducible factor (HIF) .

Product Specifications

Product Name Alternative

Von Hippel-Lindau tumor suppressor isoform 1, Von Hippel-Lindau tumor suppressor isoform 1, HRCA1, RCA1, VHL1, Von Hippel-Lindau tumor suppressor isoform 1 pVHL, G7 protein, Elongin bindingprotein, HRCA 1, RCA 1, VHL, VHL 1, VHLH, Von Hippel Lindau disease tumor suppressor, vonHippel Lindau syndrome, von Hippel Lindau tumor suppressor, AVH0616

Host

Mouse

Antigen Species

Human

Reactivity

Human

Immunogen

Recombinant human VHL (1-154aa) purified from E. coli

Clonality

Monoclonal

Isotype

IgG2b κ

Clone

AT82B10

Conjugation

Unconjugated

Applications

ELISA, WB, ICC/IF

Purification Method

By protein-A affinity chromatography

Concentration

1 mg/mL (determined by BCA assay)

Additionnal Information

VHL, ATGA0542-10 µg, ATGA0542-20 µg, ATGA0542-50 µg, ATGA0542-100 µg, ATGA0542-250 µg, ATGA0542-500 µg, ATGA0542-1 mg, ATGA0542-10, ATGA0542-20, ATGA0542-50, ATGA0542-100, ATGA0542-250, ATGA0542-500, ATGA0542-1

References & Citations

Latif F., et al. (1993) Science. 260 (5112) : 1317-20.; ; Duan DR., et al. (1995) PNAS. 92 (14) : 6459-63.; ; Maxwell PH., et al. (1999) Nature. 399 (6733) : 271-5.;

Storage Conditions

Can be stored at 2°C to 8°C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Formulation

Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol

Applications Notes

The antibody has been tested by ELISA, Western blot and ICC/IF analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

Scientific Category

Cancer

NCBI Accession Number

NP_000542

Uniprot Accession Number

P40337

WB Description

The cell lysates (40ug) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human VHL antibody (1:1000) . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.; ; Lane 1.: HepG2 cell lysate; ; Lane 2.: HeLa cell lysate; ; Lane 3.: Raji cell lysate; ; Lane 4.: Jurkat cell lysate; ; Lane 5.: A549 cell lysate; ; Lane 6.: MCF7 cell lysate; ; Lane 7.: PC3 cell lysate;

IF Description

ICC/IF analysis of VHL in Hep3B cells. The cell was stained with ATGA0542 (1:100) . The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue) .